USANA Health Sciences, Inc. (USNA) Financial Ratios
30 years of historical data (1996–2025) · Consumer Defensive · Packaged Foods
EV/EBITDA
↓
2.25
↓-63% vs avg
5yr avg: 6.05
30Y Low2.4·High18.1
P/FCF
↑
40.87
↑+96% vs avg
5yr avg: 20.84
30Y Low3.5·High67.1
P/B Ratio
↓
0.60
↓-74% vs avg
5yr avg: 2.29
30Y Low0.6·High17.4
ROE
↓
1.8%
↑-86% vs avg
5yr avg: 13.6%
30Y Low2%·High92%
Debt/EBITDA
↑
0.15
↓-15% vs avg
5yr avg: 0.18
30Y Low0.1·High1.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
USNA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
USANA Health Sciences, Inc. trades at 32.6x earnings, 65% above its 5-year average of 19.7x, sitting at the 97th percentile of its historical range. Compared to the Consumer Defensive sector median P/E of 18.8x, the stock trades at a premium of 73%. On a free-cash-flow basis, the stock trades at 40.9x P/FCF, 96% above the 5-year average of 20.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $348M | $361M | $684M | $1.0B | $1.0B | $2.1B | $1.6B | $1.8B | $2.9B | $1.8B | $1.5B |
| Enterprise Value | $204M | $217M | $541M | $720M | $753M | $1.8B | $1.3B | $1.6B | $2.7B | $1.6B | $1.4B |
| P/E Ratio → | 32.55 | 33.52 | 16.30 | 16.24 | 14.82 | 17.66 | 13.16 | 17.81 | 22.99 | 29.27 | 15.34 |
| P/S Ratio | 0.38 | 0.39 | 0.80 | 1.13 | 1.03 | 1.74 | 1.44 | 1.69 | 2.44 | 1.75 | 1.52 |
| P/B Ratio | 0.60 | 0.62 | 1.17 | 2.09 | 2.36 | 5.21 | 3.71 | 5.10 | 7.42 | 5.04 | 4.71 |
| P/FCF | 40.87 | 42.35 | 13.43 | 18.47 | 10.99 | 18.98 | 11.28 | 16.27 | 20.62 | 16.55 | 14.69 |
| P/OCF | 15.59 | 16.16 | 11.21 | 14.68 | 9.89 | 16.98 | 10.22 | 14.14 | 19.07 | 14.78 | 11.19 |
P/E links to full P/E history page with 30-year chart
USNA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
USANA Health Sciences, Inc.'s enterprise value stands at 2.3x EBITDA, 63% below its 5-year average of 6.0x. The Consumer Defensive sector median is 11.0x, placing the stock at a 80% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.23 | 0.63 | 0.78 | 0.75 | 1.55 | 1.19 | 1.49 | 2.26 | 1.51 | 1.35 |
| EV / EBITDA | 2.25 | 2.39 | 6.11 | 6.34 | 5.83 | 9.54 | 6.77 | 9.37 | 13.10 | 10.66 | 8.92 |
| EV / EBIT | 4.01 | 5.11 | 7.06 | 7.01 | 6.92 | 10.76 | 7.55 | 10.83 | 14.03 | 11.75 | 9.79 |
| EV / FCF | — | 25.42 | 10.63 | 12.82 | 8.05 | 16.93 | 9.27 | 14.37 | 19.10 | 14.31 | 13.01 |
USNA Profitability
Margins and return-on-capital ratios measuring operating efficiency
USANA Health Sciences, Inc. earns an operating margin of 5.5%, roughly in line with the Consumer Defensive sector average. Operating margins have compressed from 10.1% to 5.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 1.8% is modest, trailing the sector median of 6.5%. ROIC of 8.6% represents adequate returns on invested capital versus a sector median of 5.7%.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3% | 78.3% | 79.4% | 79.4% | 79.2% | 80.5% | 80.4% | 81.0% | 81.7% | 81.3% | 80.7% |
| Operating Margin | 5.5% | 5.5% | 7.8% | 10.1% | 10.8% | 14.3% | 15.6% | 13.8% | 15.8% | 12.7% | 13.8% |
| Net Profit Margin | 1.2% | 1.2% | 4.9% | 6.9% | 6.9% | 9.8% | 11.0% | 9.5% | 10.6% | 6.0% | 9.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1.8% | 1.8% | 7.8% | 13.7% | 16.7% | 27.8% | 31.4% | 27.1% | 33.5% | 18.2% | 33.0% |
| ROA | 1.4% | 1.4% | 6.1% | 10.4% | 11.8% | 19.1% | 21.5% | 18.8% | 23.5% | 12.6% | 22.4% |
| ROIC | 8.6% | 8.6% | 15.9% | 41.1% | 48.6% | 79.1% | 90.4% | 68.7% | 96.5% | 74.8% | 72.4% |
| ROCE | 8.3% | 8.3% | 11.8% | 19.3% | 24.7% | 38.3% | 41.3% | 37.2% | 48.1% | 37.3% | 44.4% |
USNA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
USANA Health Sciences, Inc. carries a Debt/EBITDA ratio of 0.2x, which is very conservative (96% below the sector average of 3.5x). The company holds a net cash position — cash of $158M exceeds total debt of $14M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 50.3x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.07 | 0.03 | 0.03 | 0.04 | 0.05 | 0.07 | — | — | — |
| Debt / EBITDA | 0.15 | 0.15 | 0.44 | 0.12 | 0.11 | 0.09 | 0.11 | 0.15 | — | — | — |
| Net Debt / Equity | — | -0.25 | -0.24 | -0.64 | -0.63 | -0.56 | -0.66 | -0.59 | -0.55 | -0.68 | -0.54 |
| Net Debt / EBITDA | -1.59 | -1.59 | -1.61 | -2.80 | -2.13 | -1.16 | -1.46 | -1.24 | -1.05 | -1.66 | -1.16 |
| Debt / FCF | — | -16.93 | -2.80 | -5.65 | -2.94 | -2.05 | -2.01 | -1.90 | -1.52 | -2.24 | -1.68 |
| Interest Coverage | 50.32 | 50.32 | 272.71 | 392.04 | 566.73 | 2994.72 | 351.98 | 2215.00 | 5320.72 | 2927.96 | 312.21 |
Net cash position: cash ($158M) exceeds total debt ($14M)
USNA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
USANA Health Sciences, Inc.'s current ratio of 2.24x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.45x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.52x to 2.24x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.24 | 2.24 | 2.00 | 3.52 | 2.65 | 2.26 | 2.52 | 2.41 | 2.64 | 2.41 | 2.01 |
| Quick Ratio | 1.45 | 1.45 | 1.50 | 3.00 | 2.18 | 1.65 | 1.98 | 1.90 | 2.09 | 1.96 | 1.54 |
| Cash Ratio | 1.23 | 1.23 | 1.30 | 2.78 | 2.01 | 1.49 | 1.86 | 1.73 | 1.87 | 1.75 | 1.27 |
| Asset Turnover | — | 1.25 | 1.14 | 1.46 | 1.67 | 2.05 | 1.77 | 2.05 | 2.14 | 2.02 | 2.14 |
| Inventory Turnover | 1.96 | 1.96 | 2.52 | 3.08 | 3.09 | 2.35 | 2.47 | 2.93 | 2.65 | 3.11 | 2.99 |
| Days Sales Outstanding | — | — | 3.51 | 2.85 | 2.64 | 2.20 | 2.39 | 3.01 | 4.31 | 4.69 | 6.18 |
USNA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
USANA Health Sciences, Inc. returns 7.9% to shareholders annually primarily through share buybacks. The earnings yield of 3.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.1% | 3.0% | 6.1% | 6.2% | 6.7% | 5.7% | 7.6% | 5.6% | 4.3% | 3.4% | 6.5% |
| FCF Yield | 2.4% | 2.4% | 7.4% | 5.4% | 9.1% | 5.3% | 8.9% | 6.1% | 4.8% | 6.0% | 6.8% |
| Buyback Yield | 7.9% | 7.6% | 1.4% | 1.1% | 2.5% | 8.6% | 3.5% | 8.4% | 3.6% | 2.7% | 4.2% |
| Total Shareholder Yield | 7.9% | 7.6% | 1.4% | 1.1% | 2.5% | 8.6% | 3.5% | 8.4% | 3.6% | 2.7% | 4.2% |
| Shares Outstanding | — | $19M | $19M | $19M | $19M | $20M | $21M | $23M | $25M | $25M | $25M |
Peer Comparison
Compare USNA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 USNAYou | $348M | 32.6 | 2.3 | 40.9 | 78.3% | 5.5% | 1.8% | 8.6% | 0.2 |
 NUS | $244M | 1.6 | 2.6 | 5.3 | 69.4% | 6.1% | 22.0% | 7.3% | 2.5 |
 NATR | $354M | 19.0 | 7.2 | 12.3 | 72.4% | 5.2% | 12.1% | 21.0% | 0.5 |
 NHTC | $20M | -23.7 | — | — | 73.5% | -4.5% | -3.1% | -6.5% | — |
 HLF | $1B | 5.4 | 5.7 | 4.9 | 75.6% | 8.8% | — | 24.3% | 4.2 |
 PLBY | $135M | -11.2 | 122.0 | — | 71.0% | -4.9% | -247.8% | -2.6% | 81.5 |
 ATGE | $4B | 17.6 | 10.9 | 12.9 | 56.9% | 19.1% | 16.9% | 12.8% | 2.0 |
 MGPI | $351M | -3.3 | — | 4.6 | 37.2% | -17.6% | -13.9% | -6.7% | — |
 VITL | $446M | 7.2 | 4.4 | — | 37.6% | 11.6% | 21.4% | 26.9% | 0.5 |
 AMZN | $2.6T | 34.1 | 18.5 | 341.6 | 50.3% | 11.2% | 22.3% | 14.7% | 1.0 |
 INGR | $6B | 8.8 | 5.5 | 12.1 | 25.3% | 14.4% | 17.7% | 15.5% | 1.4 |
| Consumer Defensive Median | — | 18.8 | 11.0 | 15.3 | 40.8% | 3.5% | 6.5% | 5.7% | 3.5 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
USNA — Frequently Asked Questions
Quick answers to the most common questions about buying USNA stock.
What is USANA Health Sciences, Inc.'s P/E ratio?
USANA Health Sciences, Inc.'s current P/E ratio is 32.6x. The historical average is 17.2x. This places it at the 97th percentile of its historical range.
What is USANA Health Sciences, Inc.'s EV/EBITDA?
USANA Health Sciences, Inc.'s current EV/EBITDA is 2.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 8.6x.
What is USANA Health Sciences, Inc.'s ROE?
USANA Health Sciences, Inc.'s return on equity (ROE) is 1.8%. The historical average is 40.3%.
Is USNA stock overvalued?
Based on historical data, USANA Health Sciences, Inc. is trading at a P/E of 32.6x. This is at the 97th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are USANA Health Sciences, Inc.'s profit margins?
USANA Health Sciences, Inc. has 78.3% gross margin and 5.5% operating margin.
How much debt does USANA Health Sciences, Inc. have?
USANA Health Sciences, Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.